TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells.
April 29, 2018
Cible’s smart drug platform overcomes platinum drug resistance
April 29, 2018

Tosk works to alleviate the painful, debilitating, and potentially fatal side effects of front line cancer therapies

Tosk is a dynamic drug development company dedicated to alleviating the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients who do not currently benefit from treatment. We are developing a family of what we call CompanionTM drugs that, when administered alongside certain cancer therapies, such as methotrexate, doxorubicin, cisplatin, EGFR inhibitors, and radiation — what we call parent therapies — will significantly improve patient outcomes.

In upcoming news, Tosk is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City.  Learn more and register to attend the conference at www.nyconcologyconference.com.

Leave a Reply

Your email address will not be published. Required fields are marked *